Search
for
Sort by
Research 661–690 of 1000+
- Genome-wide association study of atopic and autoimmune comorbidities in alopecia areata
- Clinical Efficacy of SPARC-Modified Mesenchymal Stem Cells for the Treatment of Dog Skin Wounds
- Stem cell-based therapies for alopecia areata: a narrative review
- Folliculotropic Mycosis Fungoides: Update on Diagnosis, Clinicopathological Stage, and Management
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
- Assessment of Vascular Circulation in Alopecia Areata Using the FMSF Technique
- Unlocking the Power of Light on the Skin: A Comprehensive Review on Photobiomodulation
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Alopecia Universalis Following Two Sequential Traffic Accidents : Possible Association with Increased Th1 and Th17 Cells and Decreased Th2 Cells
- Pinkie, the First Viable Germline Hypomorph Allele of Retinoid X Receptor Alpha, Reveals an Important Role for RXRa in Th2 Development.
- The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH
- Influence of Gushen Shengfa Pills Combined Wuling Capsules on Th1/Th2 Cytokines in Patients with Alopecia Areata Disease
- 0085 Th1/Th2 balance, IFN-γ–MHC-I axis, and regulatory T cells define therapeutic response endotypes in alopecia areata
- A case of bullous pemphigoid in a malignant melanoma patient following an increased Th2/Th1 ratio in peripheral blood cells after nivolumab treatment
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)
- Alarmin Cytokines as Central Regulators of Cutaneous Immunity
- Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
- Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
- Selective Ablation of Ctip2/Bcl11b in Epidermal Keratinocytes Triggers Atopic Dermatitis-Like Skin Inflammatory Responses in Adult Mice
- Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
- Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study
- Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
- Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
- Toll-like Receptor 3 Agonist, Polyinosinic-polycytidylic Acid, Upregulates Carbonic Anhydrase II in Human Keratinocytes
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)